[
    {
        "text": "but what it really comes down to is you know we want to know what an individual's carbohydrate tolerance is okay i mean that's key to personalization right does everybody need to be very low carbohydrate low carbohydrate i mean where does we can say population level what happens in large clinical trials but what's happening with the individual because let's face it peter and you know you and i as practicing clinicians know this when you're sitting with one patient in front of you you can go over group data from a clinical trial and that's important part of the decision making but the only thing that really matters is what's going to happen with the patient right in front of you we really want to know what the individualized reaction is going to be you know we know that this happens with a carbohydrate consumption above a certain threshold but what that certain threshold is in the individual we don't know and based on these pathways you know what is the marker we want to be looking at actually it's probably p-o-a surprisingly not a fatty acid but what this tells us is that when someone has consumed carbohydrates above their individual tolerance that poa level is going to be a great biomarker it's going to go up as again a protective mechanism in the liver our livers are really i mean you know we talk about livers all the time so related to insulin resistance it's just always amazing just how sophisticated",
        "start": "00:00:00",
        "duration": 224.07900000000004,
        "title": "The best early indicators of metabolic disease"
    },
    {
        "text": "and how our livers although we think of them as producing things that aren't necessarily good for us and that may be true they're also really working for us as well um and so again i want to also go back on one other thing that you said and the other thing that you said is so this comes you know before the adiposity and i think that that is such an important point and one i like to preach every opportunity i can get it but this is starting to happen before people gain a lot of weight okay this is a disease process in in of itself that causes obesity so you know we have to really take that into account when we're in the office with someone who's struggling for with obesity and i know peter you take this really to heart of approaching and treating these patients without bias um as i do but it's it's so important for other providers to be looking themselves in the mirror and asking themselves you know what are the biases i hold against patients who come to me struggling with their weight and what do i really know about the science and what it really one must conclude is that this is not their fault okay these are things that happened beforehand and they're suffering the consequences of it and the problem is the consequence is on full view for everyone to see it's not something that they can hide and that makes them so vulnerable to bias in health care and again one of the other things i come",
        "start": "00:01:52",
        "duration": 209.762,
        "title": "The best early indicators of metabolic disease"
    },
    {
        "text": "back to is part of our whole battle in health equity so sarah i want to keep digging into this idea because it's so interesting to me of having a leading indicator for you know this early early early warning sign you know i mean i we talked about it at the outset of this discussion which is you know in some ways the tragedy of using hemoglobin a1c as the marker of when somebody gets on the radar i mean you said it yourself patients will show up and nobody's ringing the bell until their hemoglobin a1c is above 6.5 but i mean that literally is happening 10 15 maybe 20 years after there were early early molecular warning signs and if measuring palmitoleic acid is one of them uh that's exactly the kind of stuff that i find interesting because in our practice we use cgm a lot so continuous glucose monitoring is kind of you know we don't you know non-diabetics are wearing cgm like it's no tomorrow in our practice because of that exact reason we're basically holding them to a very high standard of average glucose and high excursions and all these sorts of things i want to go back to something that you alluded to which is the association between pomelytic palmitoleic acid and triglyceride is so tight that would we miss for example african-american patients do we know if they're failing to synthesize c-161 in the way a white patient is wouldn't we love to know that there's not been a good trial looking at that i mean one of the problems that we have in research in general is that we tend to focus on white people right um you know and actually worse middle or",
        "start": "00:03:37",
        "duration": 214.96000000000004,
        "title": "The best early indicators of metabolic disease"
    },
    {
        "text": "upper middle class white people um so there are a lot of questions with this um in specific populations um there have been a couple of studies recently coming out looking specifically at what we're talking about poa um and it's marker for future problems and predictor of future diabetes and other issues one was a study recently published called the panic study looking at levels in childhood and seeing how they translate to health consequences you know decades down the road and then there was another study i believe it was from the netherlands um where they looked at poa levels at 50 to correlate them with c-reactive protein levels at age 70 right and what we see is what we would expect based on our our discussion here which is the poa was a predictor of problems down the road in people who were healthy when their poa was elevated or healthy so we thought you know what we really want to know ahead of time and i know this is very meaningful to you in your practice is i want the person who's healthy so i can get to tell them how to stay healthy okay we we talk a lot about you know trying to work on people who are already so so to speak behind the eight ball and we want to work them out and we want to regress their disease clearly an important goal but we also really if we're going to make a difference again with the individual and population wide we need to know who's headed for trouble this podcast is for general informational purposes only and does not constitute the practice of medicine",
        "start": "00:05:24",
        "duration": 228.72000000000008,
        "title": "The best early indicators of metabolic disease"
    },
    {
        "text": "nursing or other professional health care services including the giving of medical advice no doctor-patient relationship is formed the use of this information and the materials linked to this podcast is at the user's own risk the content on this podcast is not intended to be a substitute for professional medical advice diagnosis or treatment users should not disregard or delay in obtaining medical advice from any medical condition they have and they should seek the assistance of their health care professionals for any such conditions finally i take conflicts of interest very seriously for all of my disclosures and the companies i invest in or advise please visit peteratiammd.com forward slash about where i keep an up-to-date and active list of such companies",
        "start": "00:07:19",
        "duration": 106.72,
        "title": "The best early indicators of metabolic disease"
    }
]